By the year 2050, thirty-eight percent of the Korean population will be over the age of 65. Health care costs for Koreans over age 65 reached 15.4 trillion Korean won in 2011, accounting for a third of the total health care costs for the population. Chronic degenerative diseases, including coronary heart disease (CHD), drive long-term health care costs at an alarming annual rate. In the elderly population, loss of independence is one of the main reasons for this increase in health care costs. Korean heath policies place a high priority on the prevention of CHD because it is a major cause of morbidity and mortality. SUBJECTS/METHODS: This evidence-based study aims to the estimate potential health care cost savings resulting from the daily intake of omega-3 fatty acid supplementation. Potential cost savings associated with a reduced risk of CHD and the medical costs potentially avoided through risk reduction, including hospitalizations and physician services, were estimated using a Congressional Budget Office cost accounting methodology.
INTRODUCTION *
By 2050, thirty-eight percent of the Korean population will be over the age of 65 [1] . Health care costs for Koreans over age 65, measured by expenditures of the national health insurance service, reached 15.4 trillion Korean won in 2011, accounting for a third of the total health care costs for the population [2] . Chronic degenerative diseases, including coronary heart disease (CHD), drive long-term health care costs at an alarming annual rate [3] . In the elderly population, loss of independence is one of the main reasons for this rate increase. Korean heath policies place a high priority on the prevention of CHD because it is a major cause of morbidity and mortality.
The potential health benefits gained from the consumption of omega-3 fatty acids, such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been widely reported, with the predominant literature indicating that omega-3 fatty acids can prevent or reduce the risk for CHD in humans [4] . The anti-inflammatory, anti-thrombotic, and anti-atherosclerotic effects of omega-3 fatty acids are believed to play a key role in the reduction of CHD and its clinical manifestations. The use of omega-3 supplementation improves health and reduces total costs under various scenarios [5, 6] , although each study has theoretical limitations. It has been reported that giving each member of the Medicare program in the United States (US) approximately 1,800 mg of omega-3 fatty acids per day would prevent 374,000 hospitalizations from heart disease and would thus reduce hospital and physician costs by $3.2 billion over five years, as measured using the Congressional Budget Office (CBO)'s accounting methods [5] . Supplementation with omega-3 fatty acids is implicated in fewer fatal myocardial infarctions and less cardiovascular mortality, as well as cost-savings compared [8] Reduction in CHD associated with the daily intake of omega-3 fatty acids GISSI-Prevenzione Investigators 1999 [13] to no supplementation, in the US context [6] . In Korea, edible oils containing omega-3 fatty acids are registered as functional ingredients, and the consumption of omega-3 supplementation has been steadily increasing. However, no comparable study has been conducted in a Korean context so far. This evidence-based study therefore aims to determine the potential cost savings associated with encouraging the Korean older adults to consume omega-3 fatty acids. The potential health care cost savings resulting from the daily intake of approximately 1800 mg of omega-3 fatty acid supplementation will be estimated utilizing the best available evidence.
SUBJECTS AND METHODS

Model selection
A number of methods are available to estimate potential health cost savings, including cost-effectiveness and cost-benefit analyses. The selection of a model needs to be based not only on the aim of study but also on available data sources. Both cost-benefit and cost-effectiveness analyses are used to ascertain if any particular alternative is relatively cost-effective or has benefits exceeding its costs. The present study aimed to estimate cost savings associated with a decreased risk of CHD via the consumption of omega-3 fatty acids. As reflected in health claims, however, omega-3 fatty acid supplementation in Korea is currently used to improve blood flow [7] and blood lipid profiles, which are related to the intermediate health outcomes of CHD. Thus, a cost-effectiveness analysis was not suitable for our research because it could not compare alternatives with different goals. In addition, the estimation of the current cost premium of omega-3 fatty acids in Korea was difficult to obtain for a cost-benefit analysis. The CBO's cost accounting methodology, therefore, simply compares net costs and CHD outcomes of omega-3 supplementation versus no supplementation among the elderly. The CBO cost accounting convention, which has previously been used to estimate the cost savings of omega-3 fatty acids in CHD [5] , was appropriately employed to estimate gross and net costs to elderly medical security beneficiaries during a seven-year period. Potential savings could be measured through the numbers of hospitalizations avoided and the number of physician visits obviated for individuals who had consumed omega-3 fatty acids and who had thus achieved a reduction in their risk of CHD. The potential cost savings associated with a reduced risk of CHD and the potentially avoided hospitalizations and physician services were estimated.
Model structure and data sources
The target population was adults 65 years of age or older. Based on the International Classification of Diseases (7th Revision), CHD includes hypertension [essential (primary) hypertension (I10) and other hypertensive diseases (I11-I15)], stroke [intracranial hemorrhage (I60-I62), cerebral infarction (I63), and stroke, not specified as hemorrhage or infarction (I64)], CHD [acute myocardial infarction (I21-I22), other ischemic heart diseases (I20, I23-I25), heart failure (I50), atherosclerosis (I70), other heart diseases (I27-I43, I51-I52), and other cerebrovascular diseases (I65-I69)], and cardiovascular diseases [arterial embolism and thrombosis (I74), other diseases of arteries, arterioles and capillaries (I71-I72, I77-I79), and phlebitis, thrombophlebitis, and venous embolism and thrombosis (I80-I82) ].
The study model compared gross cost estimates of the daily intake of omega-3 fatty acids for new elderly medical security beneficiaries and potential cost offset associated with avoided CHD in members of the same group who could benefit from the daily use of omega-3 fatty acids. Table 1 shows the sources of the study's data. To estimate the gross costs of omega-3 consumption for new users, data on the elderly medical security beneficiaries were obtained from the National Health Insurance Statistical Yearbook for each year [8] . Percentages of elderly medical security beneficiaries who were currently taking omega-3 fatty acids were estimated based on the results of the Korean National Health and Nutrition Examination Surveys [9, 10] . The percentage of potential new users of daily omega-3 fatty acid supplements among the elderly medical security beneficiaries was estimated from the number of elderly medical security beneficiaries who currently were not using omega-3 supplementation divided by the number of elderly medical security beneficiaries × 100 (%). Because it is difficult to estimate the average annual cost associated with daily intake of omega-3 fatty acid per person in the Korean context, previously published data from the US [5] were used instead under the assumption that the cost of omega-3 fatty acid supplementation would be similar between the two countries. Amounts in US dollars were converted into Korean won using average annual exchange rates [11] . To estimate the potential cost offset associated with CHD avoided in elderly medical security beneficiaries who could benefit from the daily use of omega-3 fatty acids, the number of discharged elderly beneficiaries with CHD was obtained from the National Health Insurance Statistical Yearbook for each year [12] . The average annual medical cost per elderly medical security beneficiary with CHD included both 1) The percentage of potential new users of daily omega-3 fatty acid supplements among the elderly medical security beneficiaries was estimated from the number of elderly medical security beneficiaries who currently were not using omega-3 supplementation divided by the number of the elderly medical security beneficiaries ×100 (%). hospitalization and physician service costs [8] . The reduction in CHD associated with the daily intake of omega-3 fatty acids was assumed to be 15% based on a clinical trial studying the daily intake of 1 g of omega-3 fatty acids for patients who had suffered myocardial infarctions [13] . Table 2 illustrates that the estimate of the seven-year 
RESULTS
DISCUSSION
Our findings suggest that omega-3 supplementation in older individuals may yield substantial cost-savings by reducing the risk of CHD, consistent with previously reported results [5, 6] . In a US study using the same methodology, approximately 1,800 mg of omega-3 fatty acids per day were estimated to prevent 374,000 hospitalizations from heart disease and thus reduce hospital and physician costs by $3.2 billion across a five-year period [5] . Omega-3 supplements were likely to prevent secondary cardiovascular events in US males using decision-analytic models [6] . Various studies suggest that omega-3 intake may be positively related to other disease conditions, such as disorders of cognitive functioning [14] . Among older adults, postponing the loss of independence is important because disability puts extensive financial burden on themselves, their families, and the healthcare system. In this regard, omega-3 supplementation may have greater cost-savings than what was reported in the aforementioned study.
The lowest net cost savings in 2011 can be explained by several reasons. During 7 years gross cost estimates have increased due to increased number of elderly medical security beneficiaries and increased potential new daily users of omega-3 fatty acids among elderly medical security beneficiaries. Potential cost offsets have increased as well up to 2011 but reduction existed in 2011 due to decreased number of discharged elderly beneficiaries with CHD and thus decreased case reduction in CHD associated with the daily intake of omega-3 fatty acids. Therefore the lowest net cost savings were observed in 2011 due to the highest gross cost estimates as well as reduced potential cost offsets.
Our study had a number of limitations that should be addressed in future studies. Direct non-medical costs, such as transportation and caregiver costs, or unpaid care costs, such as lost wages for the caregiver, were not included in our model due to limited data sources. Indirect costs, such as lost earnings due to premature death and lost workdays due to illness, were not captured in the present study. However, our study population consisted of older adults, and the possibility of regular job activity for this group would be minimal. Furthermore, because some of the data used in the analyses were estimated from the best available proxies or were obtained from other nations, these data may not have been as accurate as those directly measured. Nevertheless, our study had several advantages. To date, this study was the first study to estimate the cost-savings of omega-3 supplementation among older adults in Korea. Furthermore, this study may provide valuable information for determining the type or target of interventions, prioritizing findings, and planning health policies for older persons in Korea.
